Literature DB >> 18432523

Expression of complement components and inhibitors on platelet microparticles.

Wei Yin1, Berhane Ghebrehiwet, Ellinor I B Peerschke.   

Abstract

Platelet microparticles (PMP) are released from activated platelets and play an important role in hemostasis, thrombosis and inflammation. Since platelets were recently found to demonstrate an intrinsic capacity for activating both classical and alternative pathways of the complement system, the present study extended these observations to PMP. PMP were generated by treating platelets with 10 microM A23187 (37 degrees C, 5 min). PMP were identified by flow cytometry, based on size, Annexin V binding, and expression of P-selectin and GPIIb (CD41). PMP expressed gC1qR/p33, a multifunctional cellular protein that was recently described to activate the classical complement cascade. PMP also expressed the classical pathway and contact system regulator, C1 inhibitor (C1-INH), as well as CD55 and CD59. Despite C1-INH expression, PMP supported classical pathway C4 activation in the presence of purified C1 and C4. Moreover, statistically significant deposition of C3b and C5b-9 was detected on PMP exposed to plasma, concurrently with expression of CD55 and CD59. These data provide the first evidence for the ability of PMP to support in situ complement activation. Complement activation contributes to a variety of vascular and inflammatory disease states including atherosclerosis and ischemia/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18432523      PMCID: PMC2659880          DOI: 10.1080/09537100701777311

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  50 in total

1.  Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles.

Authors:  G Tans; J Rosing; M C Thomassen; M J Heeb; R F Zwaal; J H Griffin
Journal:  Blood       Date:  1991-06-15       Impact factor: 22.113

2.  Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex.

Authors:  P J Sims; S A Rollins; T Wiedmer
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

Review 3.  The role of the complement system in ischemia-reperfusion injury.

Authors:  Thiruma V Arumugam; Ian A Shiels; Trent M Woodruff; D Neil Granger; Stephen M Taylor
Journal:  Shock       Date:  2004-05       Impact factor: 3.454

Review 4.  Cellular microparticles: a disseminated storage pool of bioactive vascular effectors.

Authors:  Olivier Morel; Florence Toti; Bénédicte Hugel; Jean-Marie Freyssinet
Journal:  Curr Opin Hematol       Date:  2004-05       Impact factor: 3.284

Review 5.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.

Authors:  Shenghe Cai; Alvin E Davis
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

Review 7.  Cellular microparticles: new players in the field of vascular disease?

Authors:  M Diamant; M E Tushuizen; A Sturk; R Nieuwland
Journal:  Eur J Clin Invest       Date:  2004-06       Impact factor: 4.686

8.  Decreased association of 45calcium with platelets unable to aggregate due to thrombasthenia or prolonged calcium deprivation.

Authors:  E I Peerschke; R A Grant; M B Zucker
Journal:  Br J Haematol       Date:  1980-10       Impact factor: 6.998

9.  Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.

Authors:  R Vlaicu; F Niculescu; H G Rus; A Cristea
Journal:  Atherosclerosis       Date:  1985-11       Impact factor: 5.162

10.  Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery.

Authors:  J N George; E B Pickett; S Saucerman; R P McEver; T J Kunicki; N Kieffer; P J Newman
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

View more
  26 in total

1.  Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.

Authors:  Osama A Hamad; Ioannis Mitroulis; Karin Fromell; Huda Kozarcanin; Triantafyllos Chavakis; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Thromb Haemost       Date:  2015-08-13       Impact factor: 5.249

2.  Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles.

Authors:  Robert Flaumenhaft; James R Dilks; Jennifer Richardson; Eva Alden; Sunita R Patel-Hett; Elisabeth Battinelli; Giannoula L Klement; Martha Sola-Visner; Joseph E Italiano
Journal:  Blood       Date:  2008-09-18       Impact factor: 22.113

Review 3.  Extracellular vesicles in renal disease.

Authors:  Diana Karpman; Anne-Lie Ståhl; Ida Arvidsson
Journal:  Nat Rev Nephrol       Date:  2017-07-24       Impact factor: 28.314

4.  Biological properties of extracellular vesicles and their physiological functions.

Authors:  María Yáñez-Mó; Pia R-M Siljander; Zoraida Andreu; Apolonija Bedina Zavec; Francesc E Borràs; Edit I Buzas; Krisztina Buzas; Enriqueta Casal; Francesco Cappello; Joana Carvalho; Eva Colás; Anabela Cordeiro-da Silva; Stefano Fais; Juan M Falcon-Perez; Irene M Ghobrial; Bernd Giebel; Mario Gimona; Michael Graner; Ihsan Gursel; Mayda Gursel; Niels H H Heegaard; An Hendrix; Peter Kierulf; Katsutoshi Kokubun; Maja Kosanovic; Veronika Kralj-Iglic; Eva-Maria Krämer-Albers; Saara Laitinen; Cecilia Lässer; Thomas Lener; Erzsébet Ligeti; Aija Linē; Georg Lipps; Alicia Llorente; Jan Lötvall; Mateja Manček-Keber; Antonio Marcilla; Maria Mittelbrunn; Irina Nazarenko; Esther N M Nolte-'t Hoen; Tuula A Nyman; Lorraine O'Driscoll; Mireia Olivan; Carla Oliveira; Éva Pállinger; Hernando A Del Portillo; Jaume Reventós; Marina Rigau; Eva Rohde; Marei Sammar; Francisco Sánchez-Madrid; N Santarém; Katharina Schallmoser; Marie Stampe Ostenfeld; Willem Stoorvogel; Roman Stukelj; Susanne G Van der Grein; M Helena Vasconcelos; Marca H M Wauben; Olivier De Wever
Journal:  J Extracell Vesicles       Date:  2015-05-14

Review 5.  Complement activation on platelets: implications for vascular inflammation and thrombosis.

Authors:  Ellinor I Peerschke; Wei Yin; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2010-06-01       Impact factor: 4.407

6.  Polyphosphate suppresses complement via the terminal pathway.

Authors:  Jovian M Wat; Jonathan H Foley; Michael J Krisinger; Linnette Mae Ocariza; Victor Lei; Gregory A Wasney; Emilie Lameignere; Natalie C Strynadka; Stephanie A Smith; James H Morrissey; Edward M Conway
Journal:  Blood       Date:  2013-12-13       Impact factor: 22.113

Review 7.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

Review 8.  Role of plasma kallikrein in diabetes and metabolism.

Authors:  E P Feener; Q Zhou; W Fickweiler
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

9.  Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.

Authors:  Ellinor I B Peerschke; Biree Andemariam; Wei Yin; James B Bussel
Journal:  Br J Haematol       Date:  2009-11-19       Impact factor: 6.998

10.  Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course.

Authors:  R Castelli; G Lambertenghi Delilliers; A Gidaro; M Cicardi; L Bergamaschini
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.